9 min
S2, Ep 1- In Drug Development, It's About Time Healthcare Matters
-
- Medicine
As we start a new year and a new season, we take a look at how drugs are developed and why time is the most important part of the formula when it comes to biopharmaceutical research. In other words, the more we delay, the longer it takes for patients to get the treatment they need.
"The researchers concluded that statin therapy, which is used everyday by patients toward lowering their cholesterol, reduced deaths by 40,000. There were 60,000 fewer hospitalizations and heart attacks and 22,000 fewer hospitalizations for strokes," says Dr. Robert Popovian, Chief Science Policy Officer at the Global Healthy Living Foundation.
Among the highlights in this episode:
1:13: Listener review
1:39: How do biopharmaceutical companies go about developing their drugs and what are the three most important steps in developing a drug?
2:04: Stage two for biopharmaceutical companies when developing a drug
2:51: Why time matters when it comes to developing a drug
3:16: The importance of time when it comes to analyzing the cost and value of the development of drugs
3:50: What's the definition of value when talking about drug development?
4:17: A look at how long it takes to get value from a drug
5:11: What does it mean for innovation when drug patents come to an end?
6:31: How does biopharmaceutical research evolve?
7:37: Robert shares his final thoughts on this legislation
Contact our hosts:
Dr. Robert Popovian, Chief Science Policy Officer at GHLF: rpopovian@ghlf.org
Conner Mertens, Patient Advocate and Community Outreach Manager at GHLF: cmertens@ghlf.org
We want to hear what you think. Send your comments, or a video or audio clip of yourself to Healthcarematters@GHLF.org.
Listen to all episodes of Healthcare Matters on our website or on your favorite podcast channel.
See omnystudio.com/listener for privacy information.
As we start a new year and a new season, we take a look at how drugs are developed and why time is the most important part of the formula when it comes to biopharmaceutical research. In other words, the more we delay, the longer it takes for patients to get the treatment they need.
"The researchers concluded that statin therapy, which is used everyday by patients toward lowering their cholesterol, reduced deaths by 40,000. There were 60,000 fewer hospitalizations and heart attacks and 22,000 fewer hospitalizations for strokes," says Dr. Robert Popovian, Chief Science Policy Officer at the Global Healthy Living Foundation.
Among the highlights in this episode:
1:13: Listener review
1:39: How do biopharmaceutical companies go about developing their drugs and what are the three most important steps in developing a drug?
2:04: Stage two for biopharmaceutical companies when developing a drug
2:51: Why time matters when it comes to developing a drug
3:16: The importance of time when it comes to analyzing the cost and value of the development of drugs
3:50: What's the definition of value when talking about drug development?
4:17: A look at how long it takes to get value from a drug
5:11: What does it mean for innovation when drug patents come to an end?
6:31: How does biopharmaceutical research evolve?
7:37: Robert shares his final thoughts on this legislation
Contact our hosts:
Dr. Robert Popovian, Chief Science Policy Officer at GHLF: rpopovian@ghlf.org
Conner Mertens, Patient Advocate and Community Outreach Manager at GHLF: cmertens@ghlf.org
We want to hear what you think. Send your comments, or a video or audio clip of yourself to Healthcarematters@GHLF.org.
Listen to all episodes of Healthcare Matters on our website or on your favorite podcast channel.
See omnystudio.com/listener for privacy information.
9 min